Personalized Pre-Surgery cocktails aim to wipe out colorectal cancer
NCT ID NCT07503639
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests different drug combinations given before surgery for locally advanced colorectal cancer. The 134 participants are grouped by their tumor's genetic markers, and each group receives a tailored treatment. The main goal is to see how often the cancer completely disappears after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-1701, SHR-8068, XELOX (capecitabine and oxaliplatin), PD-L1 antibody, cetuximab β, HRS-7058, HRS-4642, and short-course radiotherapy
- What this could lead to
- If successful, this trial could identify which drug combinations work best for different genetic subtypes of colorectal cancer, potentially increasing the chance of complete tumor disappearance before surgery.
- What could go wrong
- This is an early-phase, single-center trial with only 134 participants, so results may not apply broadly. Some drug combinations may cause significant side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.